INmune Bio Inc logo

INMB - INmune Bio Inc Share Price

$11.37 -0.2  -1.9%

Last Trade - 18/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £120.2m
Enterprise Value £116.4m
Revenue £n/a
Position in Universe 3961st / 6371
Bullish
Bearish
Unlock INMB Revenue
Momentum
Relative Strength (%)
1m +21.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -52.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, INmune Bio Inc revenues was not reported. Net loss increased 82% to $4.2M. Higher net loss reflects Interest Income decrease of 40% to $22K (income), OTHER (EXPENSE) INCOME decrease from $10K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.24 to -$0.39.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for INMB
Graphical History

Revenue

INMB Revenue Unlock INMB Revenue

Net Income

INMB Net Income Unlock INMB Revenue

Normalised EPS

INMB Normalised EPS Unlock INMB Revenue

PE Ratio Range

INMB PE Ratio Range Unlock INMB Revenue

Dividend Yield Range

INMB Dividend Yield Range Unlock INMB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
INMB EPS Forecasts Unlock INMB Revenue
Profile Summary

Inmune Bio Inc. is a clinical-stage pharmaceutical immunotherapy company. The Company is focused on developing strategies for oncology that focus on re-engineering and harnessing the innate immune system to treat the patient’s cancer. The Company’s product candidates (INMB) target cells of the innate immune system that include natural killer cells (NK cells) and myeloid derived suppressor cells, (MDSC cells). The NK cell of the innate immune system has two primary functions, such as to kill virally infected cells and to kill cancer cells. Its INB03 is a protein biologic that has beneficial effects in patients with cancer. Its initial focus is on its ability to inhibit proliferation and function of myeloid-derived suppressor cells (MDSC).

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 25, 2015
Public Since February 4, 2019
No. of Shareholders: 38
No. of Employees: 4
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 13,447,948
Free Float (0.0%)
Eligible for
ISAs
SIPPs
INMB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for INMB
Upcoming Events for INMB
Wednesday 30th September, 2020
INmune Bio Inc Annual Shareholders Meeting
Frequently Asked Questions for INmune Bio Inc
What is the INmune Bio Inc share price?

As of 18/09/20, shares in INmune Bio Inc are trading at $11.37, giving the company a market capitalisation of £120.2m. This share price information is delayed by 15 minutes.

How has the INmune Bio Inc share price performed this year?

Shares in INmune Bio Inc are currently trading at $11.37 and the price has moved by 96.11% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the INmune Bio Inc price has moved by 74.17% over the past year.

What are the analyst and broker recommendations for INmune Bio Inc?

Of the analysts with advisory recommendations for INmune Bio Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for INmune Bio Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will INmune Bio Inc next release its financial results?

INmune Bio Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the INmune Bio Inc dividend yield?

INmune Bio Inc does not currently pay a dividend.

Does INmune Bio Inc pay a dividend?

INmune Bio Inc does not currently pay a dividend.

When does INmune Bio Inc next pay dividends?

INmune Bio Inc does not currently pay a dividend.

How do I buy INmune Bio Inc shares?

To buy shares in INmune Bio Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of INmune Bio Inc?

Shares in INmune Bio Inc are currently trading at $11.37, giving the company a market capitalisation of £120.2m.

Where are INmune Bio Inc shares listed? Where are INmune Bio Inc shares listed?

Here are the trading details for INmune Bio Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: INMB
What kind of share is INmune Bio Inc?

Based on an overall assessment of its quality, value and momentum, INmune Bio Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a INmune Bio Inc share price forecast 2020?

Shares in INmune Bio Inc are currently priced at $11.37. At that level they are trading at 83.35% discount to the analyst consensus target price of 0.00.

Analysts covering INmune Bio Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.75 for the next financial year.

How can I tell whether the INmune Bio Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like INmune Bio Inc. Over the past six months, the relative strength of its shares against the market has been 0.175k%. At the current price of $11.37, shares in INmune Bio Inc are trading at 84.25% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the INmune Bio Inc PE Ratio?

We were not able to find PE ratio data for INmune Bio Inc.

Who are the key directors of INmune Bio Inc?

We were unable to find the directors for INmune Bio Inc.

Who are the major shareholders of INmune Bio Inc?

Here are the top five shareholders of INmune Bio Inc based on the size of their shareholding:

Xencor Inc Corporation
Percentage owned: 11.79% (1.59m shares)
Tesi (Raymond Joseph) Individual Investor
Percentage owned: 11.46% (1.54m shares)
Lowdell (Mark William) Individual Investor
Percentage owned: 11.2% (1.51m shares)
Moss (David J.) Individual Investor
Percentage owned: 9.1% (1.22m shares)
Toucan Capital Corp Venture Capital
Percentage owned: 5.21% (700k shares)
Similar to INMB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.